ArticleVaccine2023
COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn.
Open access · greenAbstract readMulticenter Study
In one paragraph
Article in Vaccine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
10.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Safety and Effectiveness of COVID-19 Vaccines During Pregnancy: A Living Systematic Review and Meta-analysis.Drug safety · 2024Pooled it
- A Cross-Sectional Study to Understand COVID-19 Vaccine Hesitancy Among Nursing Students and Health Workers: Implications for Future Outbreak Preparedness in South Africa.International journal of environmental research and public health · 2026Article
- Comparison of SARS-CoV-2 total and neutralizing antibody transfer to neonates from vaccinated mothers vs. mothers infected during pregnancy: an observational study.BMC pregnancy and childbirth · 2026Observational
- Assessment of safety and immunogenicity of a protein subunit COVID-19 vaccine (ABDALA) in pregnant women: a single-cohort, multicenter, observational ESPIRTA study.BMC pregnancy and childbirth · 2026Observational
- Comparative immunogenicity of COVID-19 vaccination in pregnant and non-pregnant women: a real-world cohort study.Frontiers in public health · 2026Article
- Emerging and Pandemic Pathogens: Lessons Learned From a Clinical Research Network.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Review
- Pregnancy reduces COVID-19 vaccine immunity against novel variants.NPJ vaccines · 2025Article
- Patterns and functional consequences of antibody speciation in maternal-fetal transfer of coronavirus-specific humoral immunity.PLoS pathogens · 2025Article
- A Study of Transplacental Transfer of SARS-CoV-2 Antibodies in COVID-19 Vaccinated Women in Mumbai, India.Cureus · 2025Article
- Article
- Barriers to initial COVID-19 booster among US adults who completed a primary vaccine series in the CHASING COVID cohort, September 2021-October 2022.American journal of epidemiology · 2025Article
- Evaluation of neutralizing antibody titers against SARS-CoV-2 JN.1 omicron subvariant during pregnancy - A case series study.Heliyon · 2025Article
- Development and Concordance of Binding and Neutralizing Assays to Determine SARS-CoV-2 Antibody Activity in Human Milk.Pathogens & immunity · 2025Article
- Impact of pregnant mothers' previous COVID-19 infection and vaccination on newborns' serological profiling.Frontiers in immunology · 2025Article
- Transplacental transfer of maternal SARS-CoV-2 antibodies in dichorionic and monochorionic twin pregnancies.PloS one · 2025Article
- Enhanced D614G and Omicron Variants Antibody Persistence in Infants at 2 Months of Age Following Maternal mRNA Booster Vaccination During Pregnancy or Postpartum.The Pediatric infectious disease journal · 2024Article
- Influence of Maternal and Neonatal Factors on Transplacental Passive Immunity after Vaccination against COVID-19.Vaccines · 2024Article
- IgG antibody levels against the SARS-CoV-2 spike protein in mother-child dyads after COVID-19 vaccination.Infection · 2024Article
- What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus.Obstetrics and gynecology · 2024Review
- Causes and Effects of COVID-19 Vaccine Hesitancy Among Pregnant Women and its Association with Adverse Maternal, Placental, and Perinatal Outcomes.The Yale journal of biology and medicine · 2024Review
Corrections and comments
- Update of
Authors and funding
25 authors at 16 institutions in 1 country.
Flor M MunozDepartments of Pediatrics and Molecular Virology & Microbiology, Baylor College of Medicine, and Texas Children's Hospital, Houston, TX 77030, United States. Electronic address: florm@bcm.edu.
Christine M PosavadVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98109, United States. Electronic address: cposavad@fredhutch.org.
Barbra A RichardsonVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98109, United States; Departments of Biostatistics and Global Health, University of Washington, Vaccine and Infectious Disease and Public Health Sciences Divisions, Fred Hutchinson Cancer Center, Seattle, WA 98109, United States. Electronic address: barbrar@uw.edu.
Martina L BadellDepartment of Gynecology and Obstetrics, Division of Maternal Fetal Medicine, Emory University Hospital Midtown Perinatal Center, Atlanta, GA 30308, United States. Electronic address: mbadell@emory.edu.
Katherine E BungeDepartment of Obstetrics, Gynecology and Reproductive Sciences, UPMC Magee-Womens Hospital, Pittsburgh, PA 15213, United States. Electronic address: bungke@upmc.edu.
Mark J MulliganNYU Langone Vaccine Center and Division of Infectious Diseases and Immunology, Department of Medicine, NYU Grossman School of Medicine, New York, NY 10016, United States. Electronic address: mark.mulligan@nyulangone.org.
Lalitha ParameswaranNYU Langone Vaccine Center and Division of Infectious Diseases and Immunology, Department of Medicine, NYU Grossman School of Medicine, New York, NY 10016, United States. Electronic address: lalitha.parameswaran@nyulangone.org.
Clifton W KellyStatistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutchinson Cancer Center, Seattle, WA 98109, United States. Electronic address: cwkelly@scharp.org.
Courtney Olson-ChenDepartment of Obstetrics and Gynecology, University of Rochester, Rochester, NY 14642, United States. Electronic address: courtney_olson-chen@urmc.rochester.edu.
Richard M NovakDivision of Infectious Diseases, University of Illinois, Chicago, IL 60612, United States. Electronic address: rmnovak@uic.edu.
Rebecca C BradyCincinnati Children's Hospital Medical Center, Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45229, United States. Electronic address: rebecca.brady@cchmc.org.
Marcela F PasettiCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, United States. Electronic address: mpasetti@som.umaryland.edu.
Emily A DefrancoCincinnati Children's Hospital Medical Center, Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45229, United States. Electronic address: defranee@ucmail.uc.edu.
Jeffrey S GerberDivision of Infectious Diseases, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19146, United States. Electronic address: gerberj@chop.edu.
Mallory C ShriverCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, United States. Electronic address: mallory.shriver@som.umaryland.edu.
Mehul S SutharEmory Vaccine Center, Yerkes National Primate Research Center, Department of Microbiology and Immunology, Emory School of Medicine, Emory University, Atlanta, GA 30322, United States. Electronic address: mehul.s.suthar@emory.edu.
Rhea N ColerSeattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA 98109, United States. Electronic address: Rhea.Coler@seattlechildrens.org.
Bryan J BerubeSeattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA 98109, United States. Electronic address: Bryan.Berube@seattlechildrens.org.
So Hee KimStatistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutchinson Cancer Center, Seattle, WA 98109, United States. Electronic address: skim234@scharp.org.
Jeanna M PiperNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20850, United States. Electronic address: piperj@niaid.nih.gov.
Ashley M MillerFHI 360, Durham, NC 27701, United States. Electronic address: amiller@fhi360.org.
Cristina V CardemilNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20850, United States. Electronic address: cristina.cardemil@nih.gov.
Kathleen M NeuzilCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, United States. Electronic address: kneuzil@som.umaryland.edu.
Richard H BeigiDepartment of Obstetrics, Gynecology and Reproductive Sciences, UPMC Magee-Womens Hospital, Pittsburgh, PA 15213, United States. Electronic address: beigrh@upmc.edu.
DMID 21-0004 Study Group
University of Maryland, Baltimore · USCenter for Infectious Disease Research · USCincinnati Children's Hospital Medical Center · USFred Hutch Cancer Center · USMagee-Womens Hospital · USNYU Langone Health · USUniversity of Washington · USBaylor College of Medicine · USChildren's Hospital of Philadelphia · USEmory University · USEmory University Hospital Midtown · USFamily Health International 360 · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USUniversity of Illinois Chicago · USUniversity of Rochester Medical Center · US
Funding
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - Momi-Vax DMID #21-0004 {Supplement #6}UM1AI148684 · NIAID · EMORY UNIVERSITY · PI DAVID S STEPHENS · 2020 to 2026
$77.2MVTEU SupplementUM1AI148689 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Karen L. Kotloff · 2020 to 2026
$52.7MVaccine and Treatment Evaluation Units (VTEU)-DMID 21-0004UM1AI148575 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI HANA M EL SAHLY · 2020 to 2026
$29.4MKaiser Washington VTEU supplement 20-0003UM1AI148373 · NIAID · KAISER FOUNDATION RESEARCH INSTITUTE · PI LISA A JACKSON · 2020 to 2026
$24.4MEstablishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) - DMID 21-0012UM1AI148574 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Angelica Cifuentes Kottkamp, Anoma Nellore · 2020 to 2026
$23.9MUniversity of Rochester Vaccine and Treatment Evaluation Unit (VTEU)-mRNA-1273-P204 Moderna Pediatric StudyUM1AI148450 · NIAID · UNIVERSITY OF ROCHESTER · PI Angela Ramona Branche, Ann R Falsey · 2020 to 2026
$20.6MNIAID NIH HHS UM1 AI148373NIAID NIH HHS UM1 AI148450NIAID NIH HHS UM1 AI148574NIAID NIH HHS UM1 AI148575NIAID NIH HHS UM1 AI148684NIAID NIH HHS UM1 AI148689
Abstract
The immune response to COVID-19 booster vaccinations during pregnancy for mothers and their newborns and the functional response of vaccine-induced antibodies against Omicron variants are not well characterized. We conducted a prospective, multicenter cohort study of participants vaccinated during pregnancy with primary or booster mRNA COVID-19 vaccines from July 2021 to January 2022 at 9 academic sites. We determined SARS-CoV-2 binding and live virus and pseudovirus neutralizing antibody (nAb) titers pre- and post-vaccination, and at delivery for both maternal and infant participants. Immune responses to ancestral and Omicron BA.1 SARS-CoV-2 strains were compared between primary and booster vaccine recipients in maternal sera at delivery and in cord blood, after adjusting for days since last vaccination. A total of 240 participants received either Pfizer or Moderna mRNA vaccine during pregnancy (primary 2-dose series: 167; booster dose: 73). Booster vaccination resulted in significantly higher binding and nAb titers, including to the Omicron BA.1 variant, in maternal serum at delivery and in cord blood compared to a primary 2-dose series (range 0.44-0.88 log
Indexed as
COVID-19Pregnancy Complications, InfectiousAntibodies, BlockingAntibodies, NeutralizingAntibodies, ViralCohort StudiesCOVID-19 VaccinesFemaleHumansInfant, NewbornPregnancyProspective StudiesSARS-CoV-2VaccinationAntibodies, BlockingAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesBooster vaccinationCOVID-19Neutralizing antibodiesNewbornPregnancySARS-CoV-2Transplacental antibody
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.